It may be a mechanism of cancer immune evasion, and this mechanism-driving overexpression in tumor cells seems to be a compensatory response to a pro-inflammatory tumor microenvironment with high levels of TNF-α (42), which activates NF-κB signaling and thus regulates CD47 expression (43). The gene discussed is NFKB1; the disease is neoplasm.